Targeting PID1 generates oxysterols to switch macrophage cell fates for improved antitumor immunity.

Targeting PID1 in tumor-associated macrophages produces oxysterols that reprogram macrophages toward an antitumor phenotype, enhancing immune responses in multiple cancers.

• Why it matters: Disordered cholesterol and oxysterol profiles in the tumor microenvironment contribute to immunosuppression, but their specific roles in TAMs are not well understood, limiting therapeutic options.
• What they did: The study used genetic deletion of PID1 in myeloid cells, revealing increased LDL uptake, cholesterol oxidation to specific oxysterols, and a shift from immunosuppressive to antitumor macrophages, with combined treatments further boosting antitumor effects.
• The result: This approach reprograms TAMs to support immune surveillance, offering a promising immunometabolic strategy that enhances the efficacy of chemotherapy and could improve cancer immunotherapy outcomes.